Literature DB >> 23084359

T cell affinity regulates asymmetric division, effector cell differentiation, and tissue pathology.

Carolyn G King1, Sabrina Koehli, Barbara Hausmann, Mathias Schmaler, Dietmar Zehn, Ed Palmer.   

Abstract

The strength of interactions between T cell receptors and the peptide-major histocompatibility complex (pMHC) directly modulates T cell fitness, clonal expansion, and acquisition of effector properties. Here we show that asymmetric T cell division is an important mechanistic link between increased signal strength, effector differentiation, and the ability to induce tissue pathology. Recognition of pMHC above a threshold affinity drove responding T cells into asymmetric cell division. The ensuing proximal daughters underwent extensive division and differentiated into short-lived effector cells expressing the integrin VLA-4, allowing the activated T cell to infiltrate and mediate destruction of peripheral target tissues. In contrast, T cells activated by below-threshold antigens underwent symmetric division, leading to abortive clonal expansion and failure to fully differentiate into tissue-infiltrating effector cells. Antigen affinity and asymmetric division are important factors that regulate fate specification in CD8(+) T cells and predict the potential of a self-reactive T cell to mediate tissue pathology.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23084359      PMCID: PMC3622938          DOI: 10.1016/j.immuni.2012.06.021

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  40 in total

Review 1.  Selecting and maintaining a diverse T-cell repertoire.

Authors:  A W Goldrath; M J Bevan
Journal:  Nature       Date:  1999-11-18       Impact factor: 49.962

Review 2.  Signaling takes shape in the immune system.

Authors:  M L Dustin; A C Chan
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

3.  Cutting edge: LFA-1 integrin-dependent T cell adhesion is regulated by both ag specificity and sensitivity.

Authors:  Kristen L Mueller; Mark A Daniels; Alicia Felthauser; Charlly Kao; Stephen C Jameson; Yoji Shimizu
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

4.  Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

Authors:  T A Yednock; C Cannon; L C Fritz; F Sanchez-Madrid; L Steinman; N Karin
Journal:  Nature       Date:  1992-03-05       Impact factor: 49.962

5.  Helper requirements for generation of effector CTL to islet beta cell antigens.

Authors:  Georg M N Behrens; Ming Li; Gayle M Davey; Janette Allison; Richard A Flavell; Francis R Carbone; William R Heath
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

6.  B6.C-H-2bm12. A new H-2 mutation in the I region in the mouse.

Authors:  I F McKenzie; G M Morgan; M S Sandrin; M M Michaelides; R W Melvold; H I Kohn
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

Review 7.  Dare to be different: asymmetric cell division in Drosophila, C. elegans and vertebrates.

Authors:  Jörg Betschinger; Jürgen A Knoblich
Journal:  Curr Biol       Date:  2004-08-24       Impact factor: 10.834

Review 8.  Immune responses to Listeria monocytogenes.

Authors:  Eric G Pamer
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

9.  Protection against adoptive transfer of autoimmune diabetes mediated through very late antigen-4 integrin.

Authors:  L C Burkly; A Jakubowski; M Hattori
Journal:  Diabetes       Date:  1994-04       Impact factor: 9.461

Review 10.  The thymus selects the useful, neglects the useless and destroys the harmful.

Authors:  H von Boehmer; H S Teh; P Kisielow
Journal:  Immunol Today       Date:  1989-02
View more
  83 in total

1.  Visualization of granzyme B-expressing CD8 T cells during primary and secondary immune responses to Listeria monocytogenes.

Authors:  Pierre Mouchacca; Lionel Chasson; Melissa Frick; Chloé Foray; Anne-Marie Schmitt-Verhulst; Claude Boyer
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

Review 2.  Molecular regulation of effector and memory T cell differentiation.

Authors:  John T Chang; E John Wherry; Ananda W Goldrath
Journal:  Nat Immunol       Date:  2014-12       Impact factor: 25.606

3.  Low-Affinity Memory CD8+ T Cells Mediate Robust Heterologous Immunity.

Authors:  Scott M Krummey; Ryan J Martinez; Rakieb Andargachew; Danya Liu; Maylene Wagener; Jacob E Kohlmeier; Brian D Evavold; Christian P Larsen; Mandy L Ford
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

4.  T cell avidity and tumor immunity: problems and solutions.

Authors:  Arthur A Hurwitz; Steven M Cuss; Katherine E Stagliano; Ziqiang Zhu
Journal:  Cancer Microenviron       Date:  2013-12-20

5.  Targeted loss of SHP1 in murine thymocytes dampens TCR signaling late in selection.

Authors:  Ryan J Martinez; Anna B Morris; Dennis K Neeld; Brian D Evavold
Journal:  Eur J Immunol       Date:  2016-09       Impact factor: 5.532

6.  T cells: TCR affinity goes asymmetric.

Authors:  Maria Papatriantafyllou
Journal:  Nat Rev Immunol       Date:  2012-10-29       Impact factor: 53.106

Review 7.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Implications of non-canonical G-protein signaling for the immune system.

Authors:  Cédric Boularan; John H Kehrl
Journal:  Cell Signal       Date:  2014-02-28       Impact factor: 4.315

9.  Interferon regulatory factor 4 sustains CD8(+) T cell expansion and effector differentiation.

Authors:  Shuyu Yao; Bruno Fernando Buzo; Duy Pham; Li Jiang; Elizabeth J Taparowsky; Mark H Kaplan; Jie Sun
Journal:  Immunity       Date:  2013-11-07       Impact factor: 31.745

Review 10.  To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.

Authors:  Jessica E Thaxton; Zihai Li
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.